Option chain shows key data for Lucid Diagnostics's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Lucid Diagnostics.

Lucid Diagnostics (NASDAQ:LUCD) Stock, Option Chain

Lucid Diagnostics

Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.

What Happened

News

Price Target

Markets

Analyst Ratings

Trading Ideas

BIOA

CART

CVNA

LUCD

TSLA

VRSN

Tesla To $370? Here Are 10 Top Analyst Forecasts For Monday

Biotech

Financial Advisors

Penny Stocks

Small Cap

Management

Tech

Personal Finance

General

ALUR

GEVO

KULR

Most investors&#39; definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your exact threshold, these firms remain a high-risk, high-reward proposition.

October&#39;s 4 Best Penny Stocks: High-Risk, High-Reward Picks


Most investors&#39; definition of a penny stock has broadened to include not just companies trading at less than $1 per share, but also those with slightly higher stock prices up to about $5 per share. Regardless of your

Lucid Diagnostics Inc

Press Releases

Lucid Diagnostics Completes Convertible Debt Refinancing to Strengthen Balance Sheet and Extend Cash Runway Past Key Near-Term Milestones

Prospective Clinical Utility Study of Lucid Diagnostics' EsoGuard® Esophageal DNA Test Accepted for Peer-Reviewed Publication

Lucid Diagnostics Partners with VITALExam to Enhance Esophageal Precancer Detection for Firefighters

Lucid Diagnostics Granted 180-Day Extension by Nasdaq to Regain Compliance with Minimum Bid Price Rule

Lucid Diagnostics Announces Record Quarterly EsoGuard® Test Volume

Lucid Diagnostics to Participate in the 12th Annual BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

PAVmed Regains Compliance with Nasdaq Stockholders' Equity Requirement

Contracts

Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health

Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Renowned Investigators Awarded $8 Million NIH Grant to Study Lucid Diagnostics' EsoGuard® in At-Risk Patients without Symptomatic GERD

PAVM

Apyx Medical

Baird Medical Investment Holdings Ltd - Ordinary Share

Baird Medical Investment

HeartBeam

CytoSorbents

electroCore

EDAP TMS S.A. - American Depositary Shares, each representing One Ordinary Share

Edap TMS

Fonar

Fractyl Health

Hyperfine

Kewaunee Scientific Corporation - Common Stock

Kewaunee Scientific

KORU Medical Systems, Inc. - Common Stock

KORU Medical Systems

LENSAR

Microbot Medical

Monogram Technologies Inc. - Common Stock

Monogram Technologies

Milestone Scientific

Myomo

enVVeno Medical Corporation - Common Stock

enVVeno Medical

Odysight ai

Owlet

Pro-Dex

Vicarious Surgical Inc. Class A Common Stock

Vicarious Surgical

Sight Sciences

Sensus Healthcare

Vivani Medical

JIN MEDICAL INTERNATIONAL LTD. - Ordinary Shares

Jin Medical International

Ascendiant Capital

Cantor Fitzgerald

Canaccord Genuity

Needham

Comments

Lucid Diagnostics

Lucid Diagnostics (LUCD) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga